Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
Acylsulfonamide derivative
This invention provides a novel acylsulfonamide derivative which can be used as an ACC activity inhibitor effective for the treatment of visceral fat syndrome that becomes the risk-factor of diseases of adult people such as myocardial infarction, cerebral infarction and diabetes.Particularly, it relates to an acylsulfonamide derivative represented by a general formula 1 wherein R1 is substituted/unsubstituted C2-C12 alkyl or alkoxy group or substituted/unsubstituted C2-C12 alkenyl or alkynyl group, R2 is hydrogen atom, hydroxyl group, mercapto group, substituted/unsubstituted C1-C6 alkoxy or alkylthio group, nitro group, halogen atom, trichloromethyl group, trifluoromethyl group or cyano group, R3 is substituted/unsubstituted C1-C20 alkyl or alkoxy group, substituted/unsubstituted C2-C20 alkenyl or alkynyl group, substituted/unsubstituted aromatic hydrocarbon or aromatic heterocyclic group, substituted amino group, substituted/unsubstituted C2-C20 alkenyloxy or alkynyloxy group or R4O&#8212; (wherein R4 is substituted/unsubstituted aromatic hydrocarbon or aromatic heterocyclic group), Y is &#8212;CH&boxH;CH&#8212;, &#8212;N&boxH;CH&#8212;, &#8212;CH&boxH;N&#8212;, sulfur or oxygen, and ring A is aromatic hydrocarbon, aromatic heterocyclic ring or cyclic alkyl group.
Ajinomoto Co., Inc.
C C C C
C07C C07C C07C C07C
inventional inventional inventional additional
Hiroshi Masato Takashi Keiji
Ikawa Nishimura Nakamura Okada